Jin Rong Jie·2025-08-21 02:13Core Viewpoint - China Biopharmaceutical (01177) experienced a 2.01% increase in stock price, reaching HKD 7.61 per share with a trading volume of HKD 303 million [1] Company Overview - China Biopharmaceutical is an innovative research and R&D-driven pharmaceutical group, focusing on drug development, intelligent manufacturing, and sales [1] - The company specializes in various biopharmaceuticals and chemical drugs, particularly excelling in four therapeutic areas: oncology, liver diseases, respiratory systems, and surgical/pain management [1] - Since its listing in 2000, the company has been included in multiple indices such as the MSCI Global Standard Index and the Hang Seng Index, and has been recognized in the "Top 50 Global Pharmaceutical Companies" by Pharmaceutical Manager for six consecutive years [1] - Core enterprises like Chengda Tianqing Pharmaceutical Group and Beijing Tide Pharmaceutical Co., Ltd. have consistently ranked among the top 100 pharmaceutical companies in China, with the company's product revenue share increasing year by year [1] Financial Performance - As of the mid-year report in 2025, China Biopharmaceutical reported total revenue of HKD 17.575 billion and a net profit of HKD 3.389 billion [1] Analyst Rating - On August 19,浦银国际证券 maintained a "Buy" rating for the company with a target price of HKD 9.1 [1]